Callio Therapeutics

Seattle, United States

Callio Therapeutics develops next-generation, multi-payload antibody-drug conjugates (ADCs).

$187.0M raised

Mar 2025

Series A

Biotechnology Health Care Medical

Top Investors

Norwest Venture PartnersJeito CapitalNovo HoldingsEDBIOmega Funds

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Callio Therapeutics

How much funding has Callio Therapeutics raised?

Callio Therapeutics has raised $187.0M in total funding. The most recent round was Series A. The last funding was announced in March 2025.

Who are Callio Therapeutics's investors?

Callio Therapeutics's investors include Norwest Venture Partners, Jeito Capital, Novo Holdings, EDBI, Omega Funds.

Where is Callio Therapeutics headquartered?

Callio Therapeutics is headquartered in Seattle, United States.

What does Callio Therapeutics do?

Callio Therapeutics develops next-generation, multi-payload antibody-drug conjugates (ADCs).

What stage is Callio Therapeutics at?

Callio Therapeutics is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated March 3, 2025.

MLA

"Callio Therapeutics — Funding & Investors." VCBacked, March 3, 2025, https://www.vcbacked.co/company/callio-therapeutics. Accessed June 4, 2026.

APA

VCBacked. (2025). Callio Therapeutics — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/callio-therapeutics

Wikipedia (cite web)

{{cite web |title=Callio Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/callio-therapeutics |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated March 3, 2025.

Similar Companies in Biotechnology